LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

MRK

116.3

+0.48%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

43%

57%

151 / 350 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. märts 2026, 18:58 UTC

Suurimad hinnamuutused turgudel

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

24. märts 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. märts 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

24. märts 2026, 23:33 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises, Boosted by Dollar Weakness -- Market Talk

24. märts 2026, 23:16 UTC

Market Talk

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

24. märts 2026, 22:40 UTC

Tulu

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

24. märts 2026, 21:44 UTC

Market Talk

Global Equities Roundup: Market Talk

24. märts 2026, 21:44 UTC

Market Talk

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

24. märts 2026, 20:59 UTC

Tulu

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

24. märts 2026, 20:58 UTC

Uudisväärsed sündmused

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

24. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Energy & Utilities Roundup: Market Talk

24. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

24. märts 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. märts 2026, 20:25 UTC

Tulu

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

24. märts 2026, 20:15 UTC

Market Talk

Uudisväärsed sündmused

Global Commodities Roundup: Market Talk

24. märts 2026, 20:10 UTC

Market Talk

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q Sales $378.7M >WOR

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q Adj EPS 98c >WOR

24. märts 2026, 20:10 UTC

Tulu

Worthington Enterprises 3Q EPS 92c >WOR

24. märts 2026, 19:25 UTC

Market Talk

Uudisväärsed sündmused

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

24. märts 2026, 19:06 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

24. märts 2026, 18:51 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

24. märts 2026, 18:40 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

24. märts 2026, 18:40 UTC

Market Talk

Uudisväärsed sündmused

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

24. märts 2026, 18:34 UTC

Uudisväärsed sündmused

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

24. märts 2026, 18:27 UTC

Market Talk

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

24. märts 2026, 18:21 UTC

Market Talk

Uudisväärsed sündmused

Silver Snaps 9-Session Losing Streak -- Market Talk

24. märts 2026, 18:00 UTC

Omandamised, ülevõtmised, äriostud

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

151 / 350 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.